Scrip“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office
In VivoBiopharma Financing Biopharma financings during the fourth quarter of 2022 totaled $17.5bn from 282 deals; of those, 53 financings met or exceeded the $100m mark. Overall, follow on public offerings (
ScripThe confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and
In VivoBiopharma Financing Biopharma financings during the third quarter of 2022 totaled $18.1bn from 236 deals. The largest was a $1.39bn royalty sale by Theravance Biopharma to Royalty Pharma , which acqu